Aptose Biosciences Announced That Two Abstracts On Tuspetinib, Phase 1/2 Myeloid Kinase Inhibitor For Acute Myeloid Leukemia, Have Been Accepted For Poster Presentations At The European School Of Haematology International Conference
Benzinga Newsdesk - Oct 16, 2023, 7:47AM